rate was 29.7% (95% ci: 18.5% to 41.0%), and the non-resection surgical procedures rate in the nonresection group was 27.6% (95 ci: 15.4% to 39.9%). No study provided qol data.
INTRODUCTION
Colorectal cancer (crc) is one of the leading causes of cancer death in North America 1 . The median overall survival of patients with stage iv crc managed with best supportive care alone is about 5-6 months 2 . Systemic therapy provides meaningful improvements in median survival and progression-free survival. Overall, with the judicious use of novel cytotoxic and biologic agents, the median overall survival of patients with stage iv crc has been extended to approximately 2 years [3] [4] [5] .
The optimal surgical management of stage iv crc that is not amenable to curative resection is unknown. Although administration of systemic therapy in patients with stage iv crc may convert unresectable into resectable disease, the principal goal of treatment in most patients is to prolong survival, and only about 10%-15% patients are alive at 5 years. Consequently, in patients with stage iv crc, the potential morbidity of treatment and the treatment's impact on quality of life (qol) for the patient must be considered.
Resection of the primary tumour in patients with stage iv cancer is often performed to deal with presenting primary tumour symptoms and to prevent future primary tumour complications. Potential advantages of resection of the primary tumour are prevention of obstruction and major bleeding, better pain control, and a potential reduction in serious adverse effects-such as bleeding and perforation-related to novel targeted therapy. Resection may facilitate treatment tolerance (with better response) and potentially improve survival. Conversely, newer-generation chemotherapy in combination with targeted therapy has been associated with response rates of 40%-60% [3] [4] [5] . Systemic therapy not only reduces the size of metastatic lesions, but also shrinks the primary tumour, thereby potentially reducing local complications, such as bowel obstruction, related to primary tumours. Complications after resection of a primary tumour in patients with advanced crc can delay or prevent initiation of systemic therapy and thereby preclude the associated benefit. Whether resection of the primary tumour improves disease control by reducing tumour bulk remains unknown.
The available data about the potential benefit of resection of the primary tumour-and otherwise unresectable metastatic lesions-in patients with stage iv crc are limited. Some authors have advocated for surgery [6] [7] [8] , but others have failed to demonstrate a survival benefit for resection [9] [10] [11] [12] . Whether a similar benefit can be achieved in the era of second-and third-generation anticancer agents, which are associated with higher response rates and better overall survival in patients with stage iv crc, is not known. In spite of uncertain survival benefit, a high rate of surgical resection of the primary tumour has been reported in patients with unresectable metastatic disease 13, 14 .
We undertook the present comprehensive and critical analysis of the available literature to assess if surgical resection of the primary tumour in patients with advanced crc improves outcomes.
OBJECTIVES AND OUTCOMES OF INTEREST

Primary Objective
The primary objective was to compare survival in patients with stage iv crc who did and did not undergo surgical resection of the primary tumour.
Secondary Objectives
Secondary objectives included determining
• the rates of 30-day postoperative mortality and nonfatal complications in the intervention group.
• the rate of primary tumour complications in the control group.
• the rate of non-resection procedures and the qol in both groups.
• the survival benefit of surgical intervention in the subgroup of patients treated with second-and third-generation anticancer therapy.
• the survival benefit of surgical intervention in the subgroup of minimally symptomatic patients.
DEFINITIONS
All outcomes of interest were pre-specified and defined. "Primary tumour complications" was defined as development of bleeding, obstruction, or perforation during the study period. "Fatal primary tumour complications" was defined as death within 30 days of bleeding, obstruction, or perforation secondary to an intact primary tumour. "Surgical mortality" was defined death within 30 days of surgery, and "nonfatal surgical complications" was defined as a postoperative infection, anastomotic leak, or any other complication recorded 30 days after resection of primary tumour. "Non-resection procedures" included bypass surgery with colostomy formation, endoscopic laser therapy, or placement of endoluminal stents. "Modern chemotherapy" was defined as use of third-generation agents (bevacizumab or the anti-epidermal growth factor receptor monoclonal antibodies cetuximab or panitumumab) alone or in combination with secondgeneration agents (irinotecan or oxaliplatin, or both). Second-generation chemotherapy became available for clinical use in most centres in the early 2000s. Individual patient data were not available, and so for the purposes of this analysis, all studies that specified the use of second-and third-generation therapy or those that were conducted in whole or in part (≥50%) after the year 1999 were considered studies using secondand third-generation anticancer therapy.
METHODS
Our methods conformed to the prisma statement guidelines 15 . Two investigators (SA, RKS) independently evaluated the abstracts, selected relevant articles matching the selection criteria, and independently extracted the data. The Cohen kappa coefficient was used to assess agreement between the two investigators 16 . Disagreements were resolved by discussion.
Inclusion and Exclusion Criteria
Studies involving patients with histologically documented adenocarcinoma of colon and rectum and evidence of metastases were included. Only studies with comparative data on the survival of patients with advanced crc with and without resection of the primary tumour were included. Studies that included data from patients who underwent upfront metastasectomy or from a comparison group of patients with nonsurgical procedures or curative resection were excluded. Studies were selected using the pre-specified criteria, with restriction to publication dates from 1980 onward, the English language, and studies involving human subjects. The keywords, synonyms, and controlled vocabulary (mesh, emtree) used for the literature search are described in Appendix a. The computerized literature search was augmented by a manual review of citations from relevant studies to identify additional articles for assessment. The reference lists of all retrieved articles and relevant reviews and clinical practice guidelines were retrieved for identification of additional studies. In cases of duplicate publications, the most recent or most complete study was included. A standardized form was used during full-text screening to assess eligibility of studies for inclusion in the present review.
Information
Data Collection
The data extracted from the included studies were these: study eligibility, design and characteristics, baseline patient characteristics (age, sex, comorbid illnesses, Eastern Cooperative Oncology Group performance status, etc.), primary tumour location, disease burden (extent of liver involvement, extrahepatic disease, etc.), co-interventions (radiation therapy, chemotherapy, second-and third-generation chemotherapy, metastasectomy rate, etc.), and primary and secondary outcomes (median overall survival, 2-year survival, 30-day postoperative mortality, primary tumour complications, nonsurgical procedures, and qol). Attempts were made to contact the corresponding authors of all eligible studies for relevant missing information.
Validity Assessment
Study designs were evaluated according to whether they were retrospective or prospective, and randomized or observational. Two authors independently evaluated all the included studies using a list of selected quality items assessing components of validity and bias. Disagreements were resolved by discussion. Risk of bias in the eligible studies was assessed by each reviewer using the guidelines in the Cochrane Handbook for Systematic Reviews of Interventions 17 . For observational studies, the Newcastle-Ottawa Quality Assessment Scale was applied 18 . The Newcastle-Ottawa Scale consists of 9 items grouped into 3 sections that are relevant to the quality of an observational study (Appendix b). For each outcome of interest, validity scores were evaluated as follows: ≤5, low quality; 6-7, medium quality; 8-9, high quality. The Cohen kappa coefficient was used to assess agreement between the two investigators with respect to the outcomes of interest 16 .
Analysis and Synthesis of Result
Results of the included studies for the primary outcome were combined in a formal meta-analysis to produce an overall analysis of surgical intervention. For quantitative pooling, the DerSimonian and Laird random-effects model was used, and all calculations were performed using the Review Manager analysis software (RevMan, version 5.1.2: The Cochrane Collaboration, http://ims.cochrane.org/revman). Treatment effects are expressed as hazard ratios (hrs) with corresponding 95% confidence intervals (cis). For studies that did not provide numeric information about time to events, the hr and variance were estimated using Kaplan-Meier survival curves 19 . A p value of 0.05 was used as the cut-off value for statistical significance. Funnel plots were constructed to evaluate potential publication bias. Heterogeneity across studies was assessed using a statistical test, with the proportion of variation being expressed as I 2 . All other outcomes are presented descriptively, and results are presented as the mean or median of variables in the analyzed studies. Single-group analyses were done for surgical mortality and complication rates (intervention group) and for the primary tumour complication rate (control group), because those outcomes were not applicable to both groups. A sensitivity analysis was performed if appropriate.
Pre-specified subgroup analyses were performed to assess the survival of patients with minimally symptomatic primary tumours and of patients involved in trials that offered treatment with secondand third-generation anticancer therapy. Risk of bias for all outcomes was assessed across the analyzed studies in duplicate by the two reviewers and reported using the grade scale 20 . Figure 1 shows a flow chart of the search procedure, which identified 3379 citations. Publications not meeting the inclusion criteria and duplicate publications were excluded after a review of titles and abstracts. Thirty-seven potentially eligible articles underwent full-text assessment to determine their eligibility for inclusion in the final analysis. Fifteen studies (reported in fourteen articles) were identified as meeting the eligibility criteria [6] [7] [8] [9] [10] [11] [12] [21] [22] [23] [24] [25] [26] . Kappa agreement scores between the two abstractors with respect to "screening for the citations" and "full-text screening" were 0.68 and 0.86 respectively, suggesting substantial-to-excellent agreement.
RESULTS
Study Selection
Of twenty-three full-text articles that were excluded, twelve had no comparator nonsurgical group [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] ; four used a non-resection group (that is, ostomy procedures) as comparators [39] [40] [41] [42] ; and another four used patients who underwent curative surgery as the comparator group [43] [44] [45] [46] . Two studies, each with four comparator groups, provided minimal information about those groups, and one had a patient population that overlapped with the population of another study included in the present review 14, 47 . One study whose non-resection group contained fewer than 5 patients was excluded after discussion between the reviewers 48 Table i describes the characteristics and risks of bias of the included studies. As anticipated, no prospective trial describing randomization between surgical and nonsurgical treatment was found. The study by Venderbosch et al. 7 was a retrospective analysis of two randomized studies reported by Koopman et al. 49 and Tol et al. 50 (cairo and cairo ii).
Study Characteristics and Risk of Bias
Eight studies originated in Europe; five, in North America; and one, in Asia. Six studies exclusively involved minimally symptomatic patients, and ten studies met the pre-specified criteria for use of modern anticancer therapy. All but one study 13 imposed no age restrictions.
All included publications reported retrospective observational studies. Using validity scoring for observational studies, no study met the criteria for good quality for any outcome of interest. For the primary outcome of overall survival, nine of fifteen studies were of low quality, and the remaining six were of fair quality (Appendix b).
With respect to secondary outcomes, the quality of evidence was lower overall than it had been for the primary outcome. Reporting bias was noted for all the secondary outcomes: six studies did not report the postoperative mortality rate [7] [8] [9] [10] 22 ; eight did not provide data for postoperative complications or morbidity 7, 8, 10, 13, 22, 23, 25 ; four lacked information about the rate of primary tumour complications 7, 21, 22 ; six provided no information on non-resection procedures 6, 7, 9, 24, 25 ; and no study provided information about qol.
Patient Characteristics
The included studies involved a total of 12,416 patients, among whom 8620 (69%) underwent surgery as initial treatment, and 3796 (31%) initially received systemic therapy. Several studies did not provide information about the baseline characteristics of the patients. All except one study 9 provided information about systemic therapy; eight studies provided information about performance status 7, 8, 10, 11, 22, 25, 26 ; and only four studies provided information about comorbid illnesses 6, 8, 13, 25 . The mean rate of metastasectomy was 11.4% (95% ci: 3.5% to 19.3%) in the intervention group and 9.3% (95% ci: 0% to 18.2%) in the control group.
Overall Survival
Table i describes survival and secondary outcomes for the individual studies, and Table iii describes summary findings and risk of bias for the studies overall. Median survival was 15.2 months (range: 10-30.7 months) in the resection group and 11.4 months (range: 3-22 months) in the non-resection group. A quantitative meta-analysis using the data from all fifteen studies revealed that, compared with no surgery, resection of the primary tumour was associated with a significant improvement in survival (hr: 0.69; 95% ci: 0.61 to 0.79; p < 0.00001; Figure 2 ). Subgroup analyses were performed for more homogenous patient populations with respect to symptoms and type of systemic therapy (see the Subgroup Analyses subsection).
Sensitivity Analyses
Only seven studies reported hrs and 95% cis; for the remaining 8 studies, we used the methods suggested by Tierney et al. 19 to estimate hrs and variances. In a sensitivity analysis pooling the data of seven studies 7, 8, 10, 11, 24, 26 , the hr for survival was 0.52 (95% 
Secondary Endpoints
The surgical mortality rate was reported in nine studies. The mean 30-day postoperative mortality rate was 4.9% (95% ci: 0% to 9.7%) in the intervention group. Only seven studies reported nonfatal surgical complications, including anastomotic leaks, wound infection, and other complications. The mean surgical morbidity rate was 25.9% (95% ci: 20.1% to 31.6%). Most studies did not separate major and minor complications. The mean rate of anastomotic leak, a serious postoperative complication, was 3.2% (95% ci: 0% to 8.3%)
The mean rates of primary tumour complications and intestinal obstruction secondary to the primary tumour were 29.7% (95%ci: 18.5% to 41.0%) and 23.4% (95% ci: 14.1% to 32.7%) respectively. Most studies failed to specify major and minor bleeding. No study specifically reported the rate of fatal primary tumour complications. The nonresection surgical procedures rate in the control group was 27.6% (95% ci: 15.4% to 39.9%). Only three studies reported rates of non-resection surgical procedures in the intervention group, for whom the rate was 4.2% (95% ci: 0% to 10.1%). Because all studies were retrospective, none assessed qol. 
Subgroup Analyses
Studies Using Second-and Third-Generation Anticancer Therapy
In the subgroup of patients receiving modern chemotherapy, median overall survival in the group undergoing surgery was 18.7 months (range: 11-30.7 months); it was 12.85 months (range: 5.8-22 months) in the control group. The hr for survival in this subgroup was 0.68 (95% ci: 0.56 to 0.83) compared with a hr of 0.73 (95% ci: 0.59 to 0.90) in patients treated with an older regimen, which favours surgical intervention [ Figure 2(B) ]. A test for interaction between the groups was nonsignificant. The mean 30-day postoperative mortality rate in the group treated with modern chemotherapy was 3.9% (95% ci: 0% to 11%). The mean rates of primary tumour complications and non-resection procedures in the control group were 27.4% (95% ci: 16.4% to 38.5%) and 27% (95% ci: 12.5% to 41.6%). In minimally symptomatic patients, the mean 30-day postoperative mortality rate was 1.6% (95% ci: 0% to 74.8%), with four of six studies reporting 0% surgical mortality. The mean rates of primary tumour complications and non-resection procedures in the control group were 25.6% (95% ci: 5.9% to 45.2%) and 22.2% (95% ci: 0% to 49.1%).
Studies with Minimally Symptomatic Patients
DISCUSSION
Our review demonstrates a consistent trend favouring noncurative surgical management of primary tumours in patients with stage iv crc. Overall, the group treated with surgery experienced a 31% relative improvement in survival, with an absolute survival difference of approximately 4 months. A survival benefit of similar magnitude was demonstrated in the other reviews 51, 52 ; however, a recent review did not support the surgical intervention 53 .
We found comparable survival benefits in studies using newer-generation chemotherapies and in minimally symptomatic patients. Notably, the pooled estimate for survival revealed considerable heterogeneity across studies. Conceivably, those studies involved clinically heterogeneous groups with respect to patient population (age, performance status, comorbid illnesses, disease burden, primary tumourrelated symptoms, for example) and co-interventions (type of systemic therapy, differing rate of metastasectomy). Likewise, considerable variability was noted across the different study designs, and the risk of bias was suggestive of methodologic diversity. Despite those limitations, we opted to report the pool result, because the direction of the effect was consistent across the studies and subgroups-albeit of varying magnitude.
Of special interest, a quantitative analysis excluding low-quality studies revealed a hr for survival of 0.64 (95% ci: 0.45 to 0.92) favouring surgical intervention (Appendix c, Figure c.4) . Because of selective reporting and a lack of explicit information in some studies, examination of heterogeneity with respect to important clinical variables (with the exception of underlying symptoms and type of treatment) was not feasible. Notably, the test for heterogeneity was no longer significant after exclusion from the pool of three studies that had either larger Five studies provided data about palliative radiation 10, 13, 23, 24, 26 . g One study did not provide information about chemotherapy 9 . h Six studies did not provide information 6, 11, 13, 21, 23, 24 . 1 Seven studies provided information 8, 9, [11] [12] [13] 22, 25 . ci = confidence interval; ecog = Eastern Cooperative Oncology Group. 13, 24 . Likewise, in the subgroup analysis, the test for heterogeneity was nonsignificant after exclusion of the study by Galizia et al. 11 . Because of the concern of publication bias, overestimation of the intervention effect relative to the true outcome is quite plausible.
A high rate of postoperative complications can offset the survival benefit associated with surgery. Our review was limited by selective reporting of surgical mortality and morbidity across the included studies. Compared with patients having localized disease, those with advanced crc tended to experience increased mortality after resection of the primary tumour. Although four of nine studies reported no postoperative mortality, the rate in some studies was not trivial, reaching up to 16%. As anticipated, a higher mortality rate has been associated with emergency surgery 21, 23 . Fewer than half the included studies reported nonfatal operative complications, and many failed to distinguish between major and minor complications, limiting the clinical relevance of the information.
The mean rate of primary tumour complications was 27%, but reached as high as 63%. Complication rates of more than 50% were noted mostly in older studies. Realistically, there is no evidence to suggest that response rates for the primary tumour are inferior to those for metastases. Three retrospective studies specifically investigated the risk of primary tumour complications in patients with non-resection management and reported complication rates between 3% and 17% [54] [55] [56] .
When anti-vascular endothelial growth factor therapy is combined with cytotoxic agents in patients with an intact primary tumour, a concern about perforation risk arises 57 . Two recent uncontrolled prospective studies did not support prophylactic resection of the primary tumour in minimally symptomatic patients treated with targeted therapy 58, 59 . In one cohort of 233 patients with intact primary tumours, only 7% of patients required emergency palliative surgery 58 . Use of bevacizumab, primary tumour location, and metastatic disease burden were not associated with an increased intervention rate. The other phase ii trial, which used an oxaliplatin and bevacizumab combination regimen, reported a 14% major complication rate related to the intact primary tumour 59 . Median overall survival of the treated cohort was 19.9 months. The authors concluded that survival is not compromised by leaving the primary colon tumour intact. The mean non-resection procedure rate in our review was 28% in patients with an intact primary tumour, which accorded with the primary tumour complication rate of 30% reported by McCahill et al. 59 . Only three studies reported non-resection procedures in the intervention group, and as expected, the numbers were much lower than those in the control group.
Quality of life is an important outcome that helps patients and their physicians choose appropriate treatment. No study in our review reported qol. Because major intestinal complications such as obstruction, perforation, and hemorrhage related to the primary tumour and postoperative complications are likely to be associated with a significant adverse effect on qol, qol can be indirectly assessed by reviewing the rates of surgical and primary tumour complications. A surgical intervention with a low complication rate could potentially result in a favorable qol as a result of fewer non-resection interventions, lack of primary tumour complications, and better tolerance for systemic therapy.
Potential limitations of the present review are the substantial number of low-quality studies, publication bias, and selective reporting. Importantly, all outcomes in the review were evaluated retrospectively, and patients were not randomized to surgery or non-surgical management. Several studies did not provide baseline prognostic characteristics for their groups, and others showed significant imbalances in baseline characteristics. Furthermore, few studies provided detailed information about the use and type of systemic therapy in each group, making it difficult to assess the relative contribution of resection to outcomes. Those concerns affect the validity of the survival benefit observed in our review, which might simply reflect the selection of younger and healthier patients with good performance status and low disease burden for surgery.
CONCLUSIONS
The retrospective data favour resection of the primary tumour in patients with advanced crc. However, the very low quality of the current evidence requires that good-quality cohort studies and adequately powered, well-designed randomized trials be conducted to assess all the important outcomes in this patient population. We have begun a large population-based cohort study in the province of Saskatchewan, and European investigators are currently working on several randomized trials, including cairo 4, to resolve this matter.
figure 2 (A) Hazard ratio with 95% confidence interval (ci) for overall survival, all reviewed studies, favours the intervention group [6] [7] [8] [9] [10] [11] [12] [13] [21] [22] [23] [24] [25] [26] 49 
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APPENDIX B: NEWCASTLE-OTTAWA QUALITY ASSESSMENT SCALE AND STUDY SCORES
B.1 Cohort Studies-Primary Outcome: Mortality
For a cohort study, these items are assessed:
• Selection • True representativeness of the exposed cohort in the community • Non-exposed cohort drawn from the same community • Ascertainment of exposure • Demonstration that outcome of interest was not present at start of study.
• 
B.2 Case-Control Studies
For a case-control study, these items are assessed:
